Sanofi

Genzyme Corporation

Francis Duffieux

Huawei Qiu

Qun Zhou

Nicolas Baurin

Han Li

Sunghae Park

Dorothea Kominos

Philip Janiak

Marie-Priscille Brun

Magali Mathieu

Alla Pritsker

Alexey Rak

Bruno Poirier

Patrick Grailhe

Christopher Ryan Morgan

Cyril Daveu

Engineered antibodies that are stable and can be conjugated to a ligand or drug at a ligand/drug to antibody ratio of above 3, making these conjugates suitable for treatment of a variety of indications, are provided. Methods of producing these engineered antibodies are also provided.

Modified binding polypeptides for optimized drug conjugation

The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.

Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof

Growing community of inventors

Paris, France

Francis Duffieux